ConclusionsOur study demonstrates that positive H. pylori status is a beneficial prognostic indicator in patients with gastric cancer and might suggest possible therapeutic approaches for gastric cancer. Further research is required to better understand inflammation mechanisms and cancer progression.

The safety and efficacy of S-1 plus cisplatin in Chinese advanced gastric cancer patients in first line setting is unknown. In this pilot study, patients with advanced gastric or gastro-esophageal junction adenocarcinoma were enrolled and randomly assigned in a 1:1 ratio to receive S-1 plus cisplatin (CS group) or 5-FU plus cisplatin (CF group). The primary endpoint was time to progression (TTP). Secondary end points included overall survival (OS) and safety. This study was registered on ClinicalTrials. Gov, number NCT01198392. A total of 236 patients were enrolled. Median TTP was 5.51 months in CS group compared with 4.62 months in CF group [hazard ratio (HR) 1.028, 95% confidential interval (CI) 0.758-1.394, p = 0.859]. Median OS was 10.00 months and 10.46 months in CS and CF groups (HR 1.046, 95%CI 0.709-1.543, p = 0.820), respectively. The most common adverse events in both groups were anemia, leukopenia, neutropenia, nausea, thrombocytopenia, vomiting, anorexia and diarrhea. We find that S-1 plus cisplatin is an effective and tolerable option for advanced gastric or gastro-esophageal junction adenocarcinoma patients in China.

Three series of nitronyl nitroxide radical 3d-4f compounds, namely, [LnIJhfac) 3 Cu(hfac) 2 NIT-5Br-3Py] n (Ln III = La (1), Pr (2)), [Ln(hfac) 3 Cu(hfac) 2 NIT-5Br-3Py] (Ln III = Gd (3), Tb (4), Dy ( 5)) and [Ln(hfac) 3 Cu(hfac) 2 (NIT-5Br-3Py) 2 ] n (Ln III = Gd (6), Tb (7), Dy (8); NIT-5Br-3Py = 2-(5-bromo-3-pyridyl)-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide; hfac = hexafluoroacetylacetonate) have been successfully obtained. Single crystal X-ray crystallographic analysis reveals that complexes 1 and 2 consist of 1D chains built up by Ln(hfac) 3 units bridged by the radical ligands through their NO moieties and the additional Cu ions are coordinated to the nitrogen atoms of the radicals. Complexes 3-5 are rare hetero-binuclear Cu-Ln compounds bridged by the nitronyl nitroxide radicals while complexes 6-8 possess one-dimensional chain structures with a repeating [Cu-Rad-Ln-Rad] sequence. DC magnetic studies show ferromagnetic interaction between the Ln III ion and the coordinated NO group in compounds 3-8. Tb-Cu derivatives (complexes 4 and 7) display frequency dependent ac magnetic susceptibilities, indicating slow magnetic relaxation behavior. The room-temperature photoluminescence spectra of complexes 4 and 7 exhibit strong characteristic emissions in the visible region.

The meta-analysis demonstrates that the elevated expression of miR-221 and miR-222 is associated with poor OS in patients with cancer. The miR-221/222 cluster might be used as a potential therapeutic strategy in clinical practice. More work is required to fully elucidate the role of the miR-221/222 family in human tumors.

Unprecedented octa-spin-center 2p–3d–4f compounds were obtained using a specially designed nitronyl nitroxide biradical, where the Dy analogue exhibited SMM behavior.